stoxline Quote Chart Rank Option Currency Glossary
  
Rani Therapeutics Holdings, Inc. (RANI)
0.6481  0.089 (15.86%)    11-18 16:00
Open: 0.56
High: 0.6481
Volume: 1,199,476
  
Pre. Close: 0.5594
Low: 0.5411
Market Cap: 42(M)
Technical analysis
2026-11-18 4:45:01 PM
Short term     
Mid term     
Targets 6-month :  0.81 1-year :  0.95
Resists First :  0.69 Second :  0.81
Pivot price 0.56
Supports First :  0.57 Second :  0.5
MAs MA(5) :  0.55 MA(20) :  0.57
MA(100) :  0.74 MA(250) :  0.99
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  59.6 D(3) :  37.4
RSI RSI(14): 55.8
52-week High :  1.82 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RANI ] has closed Bollinger Bands are 22.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.65 - 0.65 0.65 - 0.65
Low: 0.54 - 0.54 0.54 - 0.54
Close: 0.64 - 0.65 0.65 - 0.65
Company Description

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

Headline News

Tue, 13 Oct 2026
Rani Therapeutics to Participate in the Chardan Healthcare Conference - Yahoo Finance

Mon, 05 Oct 2026
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) - Yahoo Finance

Tue, 08 Sep 2026
Rani Therapeutics to Participate in Upcoming September Conferences - GlobeNewswire

Thu, 13 Aug 2026
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - GlobeNewswire

Tue, 26 May 2026
RANI - Rani Therapeutics Holdings Inc Stock Price and Quote - Finviz

Tue, 26 May 2026
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 115 (M)
Shares Float 82 (M)
Held by Insiders 4.9 (%)
Held by Institutions 46.9 (%)
Shares Short 8,160 (K)
Shares Short P.Month 7,120 (K)
Stock Financials
EPS -0.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.34
Profit Margin 0 %
Operating Margin -516.9 %
Return on Assets (ttm) -53 %
Return on Equity (ttm) -172.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0.04
Sales Per Share 0.04
EBITDA (p.s.) -0.28
Qtrly Earnings Growth 0 %
Operating Cash Flow -20 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -4.33
PEG Ratio 0
Price to Book value 1.85
Price to Sales 15.32
Price to Cash Flow -3.69
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android